Taidoc Technology Corporation AI Stock Analysis
Taidoc Technology Corporation (4736) AI Stock Analysis
Taidoc Technology Corporation
(TWSE:4736)
Taidoc scores moderately well, led by an exceptionally cheap valuation (4.9x earnings, 4.0% dividend yield) and an unusually strong balance sheet with minimal debt and improving return on equity. These strengths are tempered by the core business issue: revenue has fallen for three straight years from the 2022 testing boom, operating margin has contracted, and a growing portion of profit comes from non-operating income, with cash conversion below historical norms. Technically, the shares hold above their 100- and 200-day averages but have lost near-term momentum, trading under the 20- and 50-day averages with negative MACD and subdued RSI. The result is a value-and-stability story awaiting evidence that management can stabilize and re-grow the core device franchise.
Taidoc Technology Corporation (4736) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 13.41B
- Dividend Yield
- 3.96%
- Average Volume (3M)
- 298.21K
- Price to Earnings (P/E)
- 5.0
- Beta (1Y)
- 0.25
- Revenue Growth
- -5.97%
- EPS Growth
- 174.80%
- Country
- TW
- Employees
- 654
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Devices
Taidoc Technology Corporation Business Overview & Revenue Model
Company Description
TaiDoc Technology Corporation, established in 1998 and based in New Taipei City, Taiwan, is a leading global producer and distributor of a wide array of medical devices. The company's comprehensive product catalog features advanced in vitro diagnosti...
Taidoc Technology Corporation Financial Statement Overview
Summary
A fortress balance sheet (score 85) anchors the profile: debt-to-equity of just 0.12, ~77% equity funding of assets, and improving ROE of 14.7%. However, the income statement (60) shows a third consecutive year of revenue decline to NT$4.20bn — less than half the 2022 pandemic peak — and although gross margin expanded to 46.0% and net margin reached 34.3%, operating profit of NT$956mn now sits below net income, meaning non-operating income is propping up the bottom line. Cash flow (58) rebounded to NT$853mn operating and NT$602mn free cash flow after a negative 2024, but conversion of earnings into cash (~60%) is weak and the year-to-year pattern is erratic. Net: strong solvency and margins offset by shrinking core revenue and soft cash quality.
Income Statement
60NeutralBalance Sheet
85Very PositiveCash Flow
58Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.23B | 4.20B | 4.64B | 4.81B | 9.63B | 6.49B |
| Gross Profit | 1.80B | 1.93B | 2.05B | 2.07B | 5.65B | 3.21B |
| EBITDA | 930.01M | 1.10B | 1.65B | 1.19B | 4.61B | 2.74B |
| Net Income | 2.56B | 1.44B | 1.16B | 1.02B | 3.38B | 1.97B |
Balance Sheet | ||||||
| Total Assets | 14.38B | 12.78B | 12.24B | 11.91B | 12.90B | 10.52B |
| Cash, Cash Equivalents and Short-Term Investments | 6.26B | 5.23B | 4.94B | 4.73B | 5.03B | 3.08B |
| Total Debt | 941.14M | 1.16B | 1.05B | 1.09B | 636.31M | 1.26B |
| Total Liabilities | 3.02B | 2.66B | 2.72B | 2.65B | 2.91B | 2.89B |
| Stockholders Equity | 11.01B | 9.79B | 9.09B | 8.90B | 9.67B | 7.39B |
Cash Flow | ||||||
| Free Cash Flow | 780.11M | 602.17M | -536.61M | 1.06B | 2.70B | 1.59B |
| Operating Cash Flow | 1.05B | 853.39M | -181.37M | 1.17B | 3.21B | 1.92B |
| Investing Cash Flow | 152.35M | -298.12M | -52.38M | 129.57M | -573.83M | -675.07M |
| Financing Cash Flow | -1.20B | -895.55M | -977.50M | -1.46B | -1.77B | -604.80M |
Taidoc Technology Corporation Peers Comparison
Overall Rating
- TW:473668Neutral
TW:666764.1Neutral
TW:410460.5Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:4736 | 68Neutral | TWD 13.26B | 4.97 | ― | 3.96% | -5.97% | 174.80% |
| TW:6667 | 64Neutral | TWD 12.62B | 12.58 | ― | 4.81% | 28.55% | 55.47% |
| TW:4104 | 61Neutral | TWD 13.58B | 14.62 | ― | 5.96% | 11.09% | 7.11% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4736 | Taidoc Technology Corporation | 128.00 | 21.28 | 19.93% | |
| TW:4104 | Excelsior Medical Co., Ltd. | 72.10 | -5.81 | -7.45% | |
| TW:6667 | Trusval Technology Co., Ltd. | 236.00 | 7.12 | 3.11% | |
| TW:6748 | ACRO Biomedical Co., Ltd. | 168.50 | 107.65 | 176.90% | |
| TW:7780 | Daiken Biomedical Co., Ltd. | 14.95 | -1.36 | -8.31% | |
| TW:7853 | Cheng Mei Instrument Technology Co., Ltd. | 339.00 | 271.60 | 402.97% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026